HUMAN IMMUNE RESPONSE TO POLYSACCHARIDE-PROTEIN CONJUGATE VACCINES

该项目的重点是年龄相关的和T-独立的性质， 多糖，包括荚膜多糖和解毒的 脂多糖，限制了它们作为疫苗的有用性（有效性） 适用于婴儿、幼儿和免疫缺陷患者。 用于共价结合病原体多糖的合成方案 将细菌转化为医学上有用的蛋白质， 这些保护性抗原的免疫学特性。 多糖- 已经合成了6 B型肺炎球菌的蛋白质缀合物， 肺炎球菌14型，聚α-（2->8）-D-NeupNAc的荚膜 B群脑膜炎球菌和大肠杆菌K1的多糖， 志贺氏菌属，a型流感嗜血杆菌、新型隐球菌和 金黄色葡萄球菌。 这些结合疫苗的评价在 不同阶段，从实验室标准化到3期试验， 功效 此外，聚核糖醇磷酸，一种多糖交叉- 与H反应。已分离出B型流感病毒， 表征和用作当前许可结合物的补充 针对这种病原体的疫苗正在进行评估。 这项工作还在 中求进工作总

This project focusses on the age-related and T-independent properties of polysaccharides, including capsular polysaccharides and detoxified lipopolysaccharides, limit their usefulness (effectiveness) as vaccines for infants, young children and patients with immunologic deficiencies. Synthetic schemes for covalently binding the polysaccharides of pathogenic bacteria to medically useful proteins have been designed to improve the immunologic properties of these protective antigens. Polysaccharide- protein conjugates have been synthesized for pneumococcus type 6B, pneumococcus type 14, the poly alpha-(2->8)-D-NeupNAc the capsular polysaccharide of both Group B meningococcus and Escherichia coli K1, Shigella sp., Haemophilus influenzae type a, Cryptococcus neoformans and Staphylococcus aureus. Evaluation of these conjugate vaccines is at various stages, from laboratory standardization to Phase 3 trials of efficacy. In addition, polyribitol phosphate, a polysaccharide cross- reactive with H. influenzae type b has been isolated and its characterization and use as an addition to the current licensed conjugate vaccines for this pathogen is being evaluated. This work is still in progress.